Targeting Bcl-2 family proteins is a proven strategy to tackle apoptosis-resistant cancers, and the Bcl-2 inhibitor venetoclax is currently applied for the therapy of leukemias (CLL, ALL)[60]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.